tradmap

ICCC IMMUCELL CORP /DE/

$9.90 -0.35%

Updated

Healthcare · In Vitro & In Vivo Diagnostic Substances

IMMUCELL CORP /DE/ (ICCC) is a healthcare company in the In Vitro & In Vivo Diagnostic Substances industry, with a market capitalization of $90 million. Shares last traded at $9.90, 18.8% below their 52-week high. Over the past year the stock is up 48.5%. ICCC trades at a price-to-earnings ratio of 114.19, above the In Vitro & In Vivo Diagnostic Substances median of 36.58. Net profit margin is 2.6%, above the peer median of -0.9%. Revenue grew 4.3% year over year.

Market Cap
$90M
Shares Out
9.1M
EPS (TTM)
$1.04
P/E Ratio
9.52
P/S Ratio
2.93
P/B Ratio
2.87
Dividend / Share
Dividend Yield
52-Week High
$12.19
52-Week Low
$4.57
Volume
162
Avg Vol (3m)
1,065.27

Performance

1W
-0.90%
1M
-7.91%
3M
+0.41%
6M
+51.84%
YTD
+65.69%
1Y
+48.54%

Daily candles · volume · SMA(20)/SMA(50) · Databento EQUS.MINI.

Technicals

RSI (14)
41.62
SMA (50)
$10.59
SMA (200)
$7.94
Price vs SMA50
-6.50%
Price vs SMA200
+24.68%
ATR (14)
$0.36

Full technical analysis (26 indicators, D/W/M) →

Financials

Revenue
$31M
Net Income
$1M
Gross Margin
40.3%
Operating Margin
12.6%
Net Margin
2.6%
Return on Equity
2.5%
Return on Assets
1.7%
Current Ratio
4.75
Debt / Equity
0.26
Revenue Growth (YoY)
+4.3%

Latest reported annual period ending 2026-06-30 · SEC EDGAR/XBRL.

Full financials — revenue, cash flow & debt over time →

Recent earnings

PeriodEPS (diluted)Reported
Q2 2026 $0.41 2026-08-13
Q1 2026 $0.21 2026-05-14
FY 2025 $-0.12 2026-03-30
Q3 2025 $0.20 2025-11-13
Q2 2026 $0.22 2026-08-13
Q1 2026 $0.16 2026-05-14

Full earnings history →

In Vitro & In Vivo Diagnostic Substances peers

ICCC vs 14 industry peers (In Vitro & In Vivo Diagnostic Substances), by market cap. Updated

P/E vs peers
114.19 / 36.58 med
+212% premium
P/S vs peers
2.93 / 4.24 med
-31% discount
Net margin vs peers
2.6% / -0.9% med
above median
1–14 of 14
IDXXIdexx Laboratories$41.7B36.589.1625.0%-1.81%
LNTHLantheus Holdings, Inc.$6.6B23.944.2417.7%+0.17%
CLDXCelldex Therapeutics, Inc.$3.1B-10.282000.34-0.32%
NEOGNeogen Corp$2.5B-322.002.92-0.9%-1.36%
NTLAIntellia Therapeutics, Inc.$1.8B-4.44-0.63%
QDELQuidelortho Corp$955M-0.910.36-39.2%-0.11%
ACHVAchieve Life Sciences, Inc.$855M-7.49-2.18%
TKNOAlpha Teknova, Inc.$388M-23.128.87-38.4%-2.83%
MYGNMyriad Genetics Inc$309M-2.740.38-14.0%-0.31%
IMDXInsight Molecular Diagnostics Inc.$135M-2.7433.41+2.99%
ICCCIMMUCELL CORP /DE/$90M114.192.932.6%-0.35%
QCLSQ/C TECHNOLOGIES, INC.$15M-0.939.79-1.57%
BMRABIOMERICA INC$10M-2.732.31-84.8%+2.51%
CDIOCardio Diagnostics Holdings, Inc.$5M-0.84374.80-1.08%

Source: SEC EDGAR (fundamentals/EPS/dividends) · Databento EQUS.MINI (prices) · market cap & yield computed by tradmap. Informational only — not financial advice.